NeuroBo Pharmaceuticals, Inc.·4

Jul 28, 6:08 AM ET

Kim Na Yeon 4

4 · NeuroBo Pharmaceuticals, Inc. · Filed Jul 28, 2023

Insider Transaction Report

Form 4
Period: 2023-07-27
Kim Na Yeon
Director10% Owner
Transactions
  • Award

    Common Stock

    2023-07-27+87,50088,959 total
  • Award

    Common Stock

    2023-07-27+12,500101,459 total
Holdings
  • Common Stock

    (indirect: Held by E&Investment Inc.)
    4,671
  • Common Stock

    (indirect: Held by The E&Healthcare Investment Fund No. 6)
    37,373
  • Common Stock

    (indirect: Held by The E&Healthcare Investment Fund No. 7)
    62,159
  • Common Stock

    (indirect: Held by The E&Healthcare Investment Fund II)
    96,351
Footnotes (5)
  • [F1]Represents a grant of restricted stock units ("RSUs") issued to the reporting person under the Issuer's 2022 Equity Incentive Plan.
  • [F2]50% of the RSUs vested immediately, and the remainder will vest in two equal installments on each subsequent anniversary of the date of grant, subject to continuing service.
  • [F3]The share amount has been adjusted to reflect the reverse stock split effective on September 12, 2022 whereby each thirty shares issued and outstanding prior to the split were combined and converted into one share of common stock.
  • [F4]Vests on the earlier of July 27, 2024 or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to continuing service.
  • [F5]Ms. Kim is the Chief Executive Officer of E&Investment, Inc., which is the sole general partner of The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7, and as such, has voting and investment control over the shares held by E&Investment and its affiliated funds. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein.

Documents

1 file
  • 4
    tm2321997-6_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT